@TommyJohn00 Totally agree with the statements above. The increasing incidence of patients with cancer and the increasing complexity of care demand an in place highly trained workforce but current budgetary constraints require us to “do more with less”. There needs to be investment in med onc
@mhong_88@MarkHughesFdn@MOGA_ORG As you so eloquently state, the QOL benefits of specialised nursing support/care coordinators is well established. This is the first paper to demonstrate that with this QOL improvement comes health service savings that make investment in these clinicians cost effective!!!
@navstruck@KfOncology Very interested in imVIGOR especially considering the much more significant recurrence rate in this disease than seen in the DYNAMIC and considering the ongoing debate of adjuvant IO in this population…
@mhong_88@jenhelenmar Great talk indeed. The high proportion of patients that think there is good evidence for an anti cancer effect of cannabis is a scary statistic!
Join our #MedicalOncology team in Newcastle as a #ClinicalTrial Fellow. One of NSW busiest clinical research teams, gain wide experience and see many opportunities. Immediate start, FT or PT, and multi-year possible. https://t.co/buxjB63ayd Credit: Ian Nord
@mhong_88@DrCraigGedye Now what to do with the cN+ patients??? Understand why this cohort was excluded from this study but annoys me that this is an exclusion factor for all the currently recruiting neoadjuvant chemo+IO studies!
@mhong_88@DrCraigGedye It’s a shame they designed the trial with 6 cycles ddMVAC. One of the great benefits of this protocol is getting to surgery quickly after 3 or 4 cycles. The fact that only 60% completed all 6 cycles fits with my experience of toxicity. I’ll still be using aMVAC